Organovo Holdings Inc ONVO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 8:19 AM EDT
1.10quote price arrow down-0.05 (-4.34%)
Volume
10,310
Close
1.15quote price arrow up+0.03 (+2.68%)
Volume
553,334
52 week range
0.89 - 2.23
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.15
  • 52 Week High2.23
  • 52 Week High Date04/19/23
  • 52 Week Low0.89
  • 52 Week Low Date02/09/24

Key Stats

  • Market Cap11.546M
  • Shares Out10.04M
  • 10 Day Average Volume5.70M
  • Dividend-
  • Dividend Yield-
  • Beta0.84
  • YTD % Change3.6

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.15
  • 52 Week High2.23
  • 52 Week High Date04/19/23
  • 52 Week Low0.89
  • 52 Week Low Date02/09/24
  • Market Cap11.546M
  • Shares Out10.04M
  • 10 Day Average Volume5.70M
  • Dividend-
  • Dividend Yield-
  • Beta0.84
  • YTD % Change3.6

RATIOS/PROFITABILITY

  • EPS (TTM)-2.17
  • P/E (TTM)-0.53
  • Fwd P/E (NTM)-0.76
  • EBITDA (TTM)-19.499M
  • ROE (TTM)-134.07%
  • Revenue (TTM)241,999.999
  • Gross Margin (TTM)95.64%
  • Net Margin (TTM)-7,886.36%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date06/13/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Organovo Holdings Inc

 

Profile

MORE
Organovo Holdings, Inc. is a biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease...
Keith Murphy
Executive Chairman of the Board, Principal Executive Officer, Corporate Secretary
Tom Hess CPA
President, Chief Financial Officer
Address
Suite 110, 6275 Nancy Ridge Drive
San Diego, CA
92121
United States

Top Peers

SYMBOLLASTCHG%CHG
VIRI
Virios Therapeutics Inc
0.4499-0.001-0.2218%
HEPA
Hepion Pharmaceuticals Inc
2.11-0.02-0.85%
ADIL
Adial Pharmaceuticals Inc
2.17-0.15-6.47%
NCNA
NuCana PLC
3.79-0.18-4.53%
AKTX
Akari Therapeutics PLC
1.21+0.09+7.92%